Publications by authors named "Conception Nemecek"

Claim this Profile
D
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Antonio Ugolini, Mireille Kenigsberg, Alexey Rak, Francois Vallée, Jacques Houtmann, Conception Nemecek

J Med Chem· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.
Coumaran Egile, Mireille Kenigsberg, Christine Delaisi, Françoise Bégassat, Véronique Do-Vale, Conception Nemecek

Mol Cancer Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
Dominique Lesuisse, Jacques Mauger, Conception Nemecek, Sébastien Maignan, Janine Boiziau

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent IGF1-R inhibitors related to bis-azaindoles.
Conception Nemecek, William A Metz, Sylvie Wentzler, Fa-Xiang Ding, Corinne Venot

Chem Biol Drug Des· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections.
Robert Snoeck, Graciela Andrei, Bahram Bodaghi, Laurence Lagneaux, Dirk Daelemans, Conception Nemecek

Antiviral Res· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis